6 citations
,
January 1996 in “Endocrine-related Cancer” Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.
5 citations
,
April 2011 in “Bioorganic & Medicinal Chemistry Letters” New Finasteride conjugate improves prostate treatment and vital signs in rats.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
223 citations
,
January 2000 in “BioFactors” Food-derived peptides may help prevent diseases like high blood pressure and high cholesterol, and can support the immune system.
2 citations
,
November 2024 in “In Silico Pharmacology” 3 citations
,
October 1993 in “Endocrinology” July 2025 in “Journal of Investigative Dermatology”
13 citations
,
November 2014 in “Toxicology Letters” Finasteride affects UGT1A4 enzyme, but not enough to cause issues when combined with other drugs.
47 citations
,
November 1982 in “Journal of Cardiovascular Pharmacology” Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.
April 2017 in “The Journal of urology/The journal of urology” Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
October 2025 in “Scientific Reports” Serenoa repens extract shows promise as a natural treatment for prostate cancer.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
21 citations
,
April 2008 in “Toxicologic Pathology” CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
July 2015 in “Pharmacological Reports” Finasteride weakens the bone-protective effects of certain blockers in low androgen conditions.
Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.
Ivarmacitinib effectively regrows hair in severe alopecia areata.
26 citations
,
July 2007 in “Biochemical Pharmacology” ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.
22 citations
,
June 2018 in “Journal of Neuroinflammation” Procyanidins from grape seeds reduce nerve pain by blocking specific proteins and inflammation.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
3 citations
,
September 2008 in “Current signal transduction therapy” Drugs that block GSK-3 show promise for treating various diseases.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
November 2025 in “Frontiers in Oncology” Sphaeranthus indicus and silver nanoparticles can help treat liver cancer by killing cancer cells.
9 citations
,
November 2013 in “BMC Pharmacology and Toxicology” Suppressing eIF4E can prevent hair loss from chemotherapy.
1 citations
,
July 2022 in “Journal of Cataract and Refractive Surgery” Certain medications and conditions increase the risk of intraoperative floppy-iris syndrome.
1 citations
,
February 2022 in “Brain Research Bulletin” Finasteride may help reduce impulsivity caused by pramipexole.
April 2017 in “Journal of Investigative Dermatology” Targeted siRNA therapy may be a promising treatment for KID syndrome by reducing mutant gene expression and improving cell communication.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.